See more : Intellicheck, Inc. (IDN) Income Statement Analysis – Financial Results
Complete financial analysis of Pulmatrix, Inc. (PULM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pulmatrix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Ollie’s Bargain Outlet Holdings, Inc. (OLLI) Income Statement Analysis – Financial Results
- Jarllytec Co. , Ltd. (3548.TWO) Income Statement Analysis – Financial Results
- ArcelorMittal S.A. (MT.AS) Income Statement Analysis – Financial Results
- The Chukyo Bank, Limited (8530.T) Income Statement Analysis – Financial Results
- Raffles Medical Group Ltd (RAFLF) Income Statement Analysis – Financial Results
Pulmatrix, Inc. (PULM)
About Pulmatrix, Inc.
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.30M | 6.07M | 5.17M | 12.63M | 7.91M | 153.00K | 335.00K | 835.00K | 1.20M | 352.00K | 653.00K | 0.00 |
| Cost of Revenue | 15.52M | 1.55M | 15.38M | 0.00 | 12.85M | 12.97M | 10.24M | 10.15M | 7.19M | 6.59M | 8.56M | 0.00 |
| Gross Profit | -8.22M | 4.53M | -10.21M | 12.63M | -4.94M | -12.81M | -9.91M | -9.32M | -5.99M | -6.24M | -7.91M | 0.00 |
| Gross Profit Ratio | -112.63% | 74.55% | -197.58% | 100.00% | -62.39% | -8,374.51% | -2,957.61% | -1,115.81% | -498.42% | -1,772.16% | -1,211.49% | 0.00% |
| Research & Development | 15.52M | 18.24M | 15.38M | 15.61M | 12.85M | 12.97M | 10.24M | 10.15M | 7.19M | 1.38M | 258.00K | 20.00K |
| General & Administrative | 6.52M | 6.78M | 6.38M | 6.89M | 8.49M | 7.52M | 7.57M | 8.02M | 9.63M | 1.74M | 265.00K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.40M | 0.00 | 0.00 | 0.00 |
| SG&A | 6.52M | 6.78M | 6.38M | 6.89M | 8.49M | 7.52M | 7.57M | 8.02M | 17.03M | 1.74M | 265.00K | 0.00 |
| Other Expenses | 0.00 | -198.00K | -11.00K | -239.00K | -205.00K | 22.00K | 0.00 | 7.53M | 0.00 | 0.00 | 0.00 | 10.00K |
| Operating Expenses | 22.04M | 25.02M | 21.76M | 22.50M | 21.33M | 20.48M | 17.81M | 18.17M | 24.22M | 3.12M | 523.00K | 30.00K |
| Cost & Expenses | 22.04M | 25.02M | 21.76M | 22.50M | 21.33M | 20.48M | 17.81M | 18.17M | 24.22M | 3.12M | 523.00K | 30.00K |
| Interest Income | 867.00K | 309.00K | 7.00K | 82.00K | 301.00K | 27.00K | 0.00 | 0.00 | 17.00K | 17.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 186.00K | 643.00K | 881.00K | 953.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.48M | 1.55M | 1.24M | 1.04M | 765.00K | 231.00K | 246.00K | 250.00K | 232.00K | 2.00K | 352.00K | 0.00 |
| EBITDA | -13.27M | -17.40M | -15.35M | -9.86M | -13.24M | -20.15M | -17.17M | -29.67M | -25.21M | -3.12M | -3.12M | -30.00K |
| EBITDA Ratio | -181.76% | -312.09% | -251.75% | 3.72% | -158.82% | -13,122.88% | -5,142.99% | -2,045.75% | -1,897.25% | -885.23% | -80.09% | 0.00% |
| Operating Income | -14.74M | -18.95M | -20.17M | -573.00K | -20.69M | -20.33M | -17.48M | -24.87M | -23.02M | -3.12M | -523.00K | -30.00K |
| Operating Income Ratio | -201.97% | -312.09% | -390.15% | -4.54% | -261.59% | -13,288.24% | -5,216.42% | -2,977.96% | -1,916.57% | -885.80% | -80.09% | 0.00% |
| Total Other Income/Expenses | 619.00K | 111.00K | -4.00K | -9.45M | 96.00K | -232.00K | -581.00K | -5.94M | -3.15M | -17.44M | 5.32M | 0.00 |
| Income Before Tax | -14.12M | -18.84M | -20.17M | -19.31M | -20.60M | -20.56M | -18.06M | -30.80M | -26.17M | -3.12M | -523.00K | -30.00K |
| Income Before Tax Ratio | -193.49% | -310.26% | -390.23% | -152.83% | -260.38% | -13,439.87% | -5,389.85% | -3,688.86% | -2,178.77% | -885.80% | -80.09% | 0.00% |
| Income Tax Expense | 0.00 | -111.00K | 2.33M | 9.21M | -205.00K | 68.00K | -62.00K | -2.96M | 2.20M | -15.07M | -2.60M | 0.00 |
| Net Income | -14.12M | -18.73M | -22.51M | -28.52M | -20.39M | -20.56M | -18.06M | -27.84M | -26.17M | -3.12M | -523.00K | -30.00K |
| Net Income Ratio | -193.49% | -308.43% | -435.38% | -225.70% | -257.79% | -13,439.87% | -5,389.85% | -3,334.49% | -2,178.77% | -885.80% | -80.09% | 0.00% |
| EPS | -3.87 | -5.43 | -8.31 | -19.83 | -24.37 | -99.67 | -186.42 | -375.87 | -646.91 | -765.72 | -130.75 | -0.18 |
| EPS Diluted | -3.87 | -5.43 | -8.31 | -19.83 | -24.37 | -99.67 | -186.42 | -375.87 | -646.91 | -765.72 | -130.75 | -0.18 |
| Weighted Avg Shares Out | 3.65M | 3.45M | 2.71M | 1.44M | 836.70K | 206.32K | 96.86K | 74.08K | 40.45K | 4.07K | 4.00K | 170.00K |
| Weighted Avg Shares Out (Dil) | 3.65M | 3.45M | 2.71M | 1.44M | 836.70K | 206.32K | 96.86K | 74.08K | 40.45K | 4.07K | 4.00K | 170.00K |
Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine
Corrected: Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio
Pulmatrix Reports 2020 Financial Results and Provides Business Update
Pulmatrix Announces $40 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Source: https://incomestatements.info
Category: Stock Reports